help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Imani, B.
Right arrow Articles by Fauser, B. C. J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Imani, B.
Right arrow Articles by Fauser, B. C. J. M.
The Journal of Clinical Endocrinology & Metabolism Vol. 85, No. 2 676-682
Copyright © 2000 by The Endocrine Society


Original Studies

Free Androgen Index and Leptin Are the Most Prominent Endocrine Predictors of Ovarian Response during Clomiphene Citrate Induction of Ovulation in Normogonadotropic Oligoamenorrheic Infertility1

Babek Imani, Marinus J. C. Eijkemans, Frank H. de Jong, Nadia N. Payne, Philippe Bouchard, Linda C. Giudice and Bart C. J. M. Fauser

Division of Reproductive Medicine, the Department of Obstetrics and Gynecology (B.I., B.C.J.M.F.), Center for Clinical Decision Sciences, and the Departments of Public Health (M.J.C.E.) and Internal Medicine III (F.H.J.), Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands; Cobbold Laboratories (N.P.), Middlesex Hospital, WIN 8AA London, United Kingdom; Service d’Endocrinologie (P.B.), Hopital Saint Antoine, 75571 Paris, France; and the Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Stanford University Medical Center (L.C.G.), Stanford, California

Address all correspondence and requests for reprints to: Prof. B. C. J. M. Fauser, M.D., Ph.D., Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Erasmus University Medical Center, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. E-mail: fauser{at}gyna.azr.nl

We have previously demonstrated that obese hyperandrogenic amenorrheic women are less likely to ovulate after clomiphene citrate (CC) medication. The present study was designed to identify whether additional endocrine screening characteristics, all potentially involved in ovarian dysfunction in 182 normogonadotropic oligoamenorrheic infertile women, are associated with ovarian response, which may improve overall prediction of CC-resistant anovulation. Standardized endocrine screening took place before initiation of CC medication (50 mg/day; increasing doses up to 150 mg/day if required) from cycle days 3–7. Screening included serum assays for fasting insulin and glucose, insulin-like growth factor I (IGF-I), IGF-binding protein-1 (IGFBP-1), IGFBP-3, free IGF-I, inhibin B, leptin, and vascular endothelial growth factor. Forty-two women (22% of the total group) did not ovulate at the end of follow-up (a total number of 325 cycles were analyzed). Fasting serum insulin, insulin/glucose ratio, IGFBP-1, and leptin were all significantly different in univariate analyses (P <= 0.02), comparing CC responders vs. nonresponders. Forward stepwise multivariate analyses in combination with factors reported earlier for prediction of patients remaining anovulatory after CC revealed a prediction model including 1) free androgen index (FAI = testosterone/sex hormone-binding globulin ratio), 2) cycle history (oligomenorrhea or amenorrhea), 3) leptin level, and 4) mean ovarian volume. These data suggest that decreased insulin sensitivity, hyperandrogenemia, and obesity, all associated with polycystic ovary syndrome, are prominent factors involved in ovarian dysfunction, preventing these ovaries from responding to stimulation by raised endogenous FSH levels due to CC medication. By using leptin instead of body mass index or waist to hip ratio, the previous model for prediction of patients remaining anovulatory after CC medication could be slightly improved (area under the curve from 0.82–0.85). This may indicate that leptin is more directly involved in ovarian dysfunction in these patients. The capability of insulin and IGFBP-1 to predict patients who remain anovulatory after CC disappears when FAI enters into the model due to a significant correlation between FAI and these endocrine parameters. This suggests that markers for insulin sensitivity (e.g. IGFBP-1 and insulin) are associated with abnormal ovarian function through its correlation with androgens, whereas leptin is directly involved in ovarian dysfunction.




This article has been cited by other articles:


Home page
Hum Reprod UpdateHome page
B.C.J.M. Fauser, K. Diedrich, P. Devroey, and on behalf of the Evian Annual Reproduction (EVAR)
Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation
Hum. Reprod. Update, January 1, 2008; 14(1): 1 - 14.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. J. Moran, M. Noakes, P. M. Clifton, and R. J. Norman
The Use of Anti-Mullerian Hormone in Predicting Menstrual Response after Weight Loss in Overweight Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3796 - 3802.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
L. J Moran, M. Noakes, P. M Clifton, G. A Wittert, G. Williams, and R. J Norman
Short-term meal replacements followed by dietary macronutrient restriction enhance weight loss in polycystic ovary syndrome
Am. J. Clinical Nutrition, July 1, 2006; 84(1): 77 - 87.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. Codner, N. Soto, P. Lopez, L. Trejo, A. Avila, F. C. Eyzaguirre, G. Iniguez, and F. Cassorla
Diagnostic Criteria for Polycystic Ovary Syndrome and Ovarian Morphology in Women with Type 1 Diabetes Mellitus
J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2250 - 2256.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M. J.C. Eijkemans, S. Polinder, A. G.M.G.J. Mulders, J. S.E. Laven, J.D. F. Habbema, and B. C.J.M. Fauser
Individualized cost-effective conventional ovulation induction treatment in normogonadotrophic anovulatory infertility (WHO group 2)
Hum. Reprod., October 1, 2005; 20(10): 2830 - 2837.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
E. J P van Santbrink, F. P Hohmann, M. J C Eijkemans, J. S E Laven, and B. C J M Fauser
Does metformin modify ovarian responsiveness during exogenous FSH ovulation induction in normogonadotrophic anovulation? A placebo-controlled double-blind assessment
Eur. J. Endocrinol., April 1, 2005; 152(4): 611 - 617.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
S. Luisi, P. Florio, F. M. Reis, and F. Petraglia
Inhibins in female and male reproductive physiology: role in gametogenesis, conception, implantation and early pregnancy
Hum. Reprod. Update, March 1, 2005; 11(2): 123 - 135.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
R. S. Legro, E. Myers, and for the Reproductive Medicine Network
Surrogate end-points or primary outcomes in clinical trials in women with polycystic ovary syndrome?
Hum. Reprod., August 1, 2004; 19(8): 1697 - 1704.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
R. J. Norman, M. Noakes, R. Wu, M. J. Davies, L. Moran, and J. X. Wang
Improving reproductive performance in overweight/obese women with effective weight management
Hum. Reprod. Update, May 1, 2004; 10(3): 267 - 280.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)
Hum. Reprod., January 1, 2004; 19(1): 41 - 47.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
E.J.P. van Santbrink and B.C.J.M. Fauser
Is there a future for ovulation induction in the current era of assisted reproduction?
Hum. Reprod., December 1, 2003; 18(12): 2499 - 2502.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M. J.C. Eijkemans, B. Imani, A. G.M.G.J. Mulders, J.D. F. Habbema, and B. C.J.M. Fauser
High singleton live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO 2)
Hum. Reprod., November 1, 2003; 18(11): 2357 - 2362.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
J. S.E. Laven, B. Imani, M. J.C. Eijkemans, F. H. de Jong, and B. C.J.M. Fauser
Absent biologically relevant associations between serum inhibin B concentrations and characteristics of polycystic ovary syndrome in normogonadotrophic anovulatory infertility
Hum. Reprod., July 1, 2001; 16(7): 1359 - 1364.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Gill, A. E. Taylor, K. A. Martin, C. K. Welt, J. M. Adams, and J. E. Hall
Specific Factors Predict the Response to Pulsatile Gonadotropin-Releasing Hormone Therapy in Polycystic Ovarian Syndrome
J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2428 - 2436.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. S. E. Laven, S. Lumbroso, C. Sultan, and B. C. J. M. Fauser
Dynamics of Ovarian Function in an Adult Woman with McCune-Albright Syndrome
J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2625 - 2630.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2000 by The Endocrine Society